Navigation Links
Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division

INDIANAPOLIS, Sept. 18 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that Robert J. Heine, M.D., Ph.D., F.R.C.P., will join Lilly in January, 2008, as Executive Medical Director for the Diabetes and Endocrine division responsible for development of Lilly's expanding diabetes and obesity R&D portfolio. Dr. Heine replaces Dr. Meng Hee Tan, Distinguished Medical Fellow, Diabetes and Endocrine, who will retire at the end of September after 8 years of outstanding service to the company.

"Lilly has a growing and exciting diabetes and obesity R&D portfolio that demands exceptional clinical leadership to guide and successfully develop," said Vince Mihalik, Vice President and Global Brand Development Platform Leader, Diabetes, Obesity and Endocrine. "Robert is widely recognized and respected in the diabetes community for his scientific and clinical excellence and his considerable leadership abilities. He'll be a fantastic addition to the Lilly team."

Heine is currently professor of diabetology in the Department of Endocrinology and director of the Diabetes Centre at the VU (Vrije Universiteit) University Medical Center in Amsterdam, Netherlands. In addition to involvement in several research projects, Heine holds positions within the European Association for the Study of Diabetes (EASD), the European Foundation for the Study of Diabetes (EFSD) and the American Diabetes Association (ADA), including chair of the EASD subcommittee for Clinical Research Training, president of the organizing committee for the 2007 EASD annual meeting, and a member of the ADA Expert Committee on guidelines for the treatment of hyperglycemia in type 2 diabetes. He is a prolific author, with more than 350 published papers, and currently serves as associate editor of Diabetic Medicine and an editorial board member for several other publications. Heine's primary research interests include the epidemiology and pathophysiology of type 2 diabetes.

"We couldn't be more pleased that Dr. Heine has decided to bring his considerable talents to Lilly," said David Moller, M.D., Vice President, Endocrine and Cardiovascular Research and Clinical Investigation, Lilly Research Laboratories. "Robert's outstanding clinical experience and depth of scientific expertise will be a major contributor to the sustained leadership of Lilly in diabetes and related metabolic disorders as we continue to bring novel medicines to patients in need around the world."

"It's a privilege to join a team with such an impressive history of innovation and one that is also shaping the future of diabetes care," said Heine. "I'm excited for the opportunity to work in a new and dynamic atmosphere at Lilly with a group of truly talented scientists."

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at


(Logo: )

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Crohns Patient Robert Hill’s greatest achievemen
2. Relapse in Risk Management System Claims the Life of Robertson
3. Robert Wood Johnson Foundation Pledges $500M To Fund Anti-Obesity Programs
4. Distinguished Scientist Award Conferred on Manchester Dentist
5. Distinguished Scientist Award Conferred on University of Rochester Scientists for Work on Preventing Cavities
6. Is Diabetes the Leading Cause of Kidney Failure in India
7. Diabetes and Depression often go hand-in-hand
8. Vitamin E, the latest warrior against diabetes
9. Thirty minutes of work up per day reduces the risk of Diabetes
10. New Drug for Diabetes
11. Diabetes, obesity rates shooting up
Post Your Comments:
(Date:11/27/2015)... ... ... ProSidebar: Fashion is a set of 30 kinetic edge graphics ... editors can easily add an informative sidebar to any FCPX production. Create lists, ... self-animating drop zones, lines, bars, and text with the ease of FCPX's drag and ...
(Date:11/27/2015)... ... 2015 , ... A simply groundbreaking television series, "Voices in America", which is ... an array of issues that are presently affecting Americans. Dedicated to providing the world ... is changing the subjects consumers focus on, one episode at a time. , ...
(Date:11/27/2015)... IL (PRWEB) , ... November 27, 2015 , ... ... of the largest, most successful and prominent nonprofit healthcare organizations in the country. ... governance involvement with various organizations, and helped advance the healthcare industry as a ...
(Date:11/26/2015)... ... 2015 , ... Patients at Serenity Point Recovery, a holistic ... Thanksgiving Day to share the things that they are most grateful for today. ... channel, patients displayed what they wrote on index cards, describing the things that ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug Delivery ... to integrate dose form selection in early phase drug development. The first of ... and bringing together the UK’s emerging life sciences companies, corporate partners, and investors, ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... 26, 2015 ... the "2016 Global Tumor Marker Testing ... and Sales Segment Forecasts, Innovative Technologies, Instrumentation ... to their offering. --> ... "2016 Global Tumor Marker Testing Market: ...
(Date:11/26/2015)... Netherlands , November 26, 2015 ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy ... Netherlands has found that immunotherapy can be ...
(Date:11/26/2015)... -- 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ... transplantation is expected to boost the market growth, as 3D ... --> 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ...
Breaking Medicine Technology: